Navigation Links
BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
Date:2/27/2013

BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it is marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions.  Additionally, BDSI is developing a high dose formulation of buprenorphine in combination with naloxone (BNX) for the treatment of opioid dependence.  Both BEMA Buprenorphine and BNX are in Phase 3 clinical development.  BDSI's headquarters is located in Raleigh, North Carolina.  For more information visit www.bdsi.com.

Cautionary Note on Forward-Looking Statements

This press release, the presentations discussed herein and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will,"
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
2. BioDelivery Sciences Announces Completion of BNX Safety Study
3. BioDelivery Sciences Announces $40 Million Registered Financing
4. BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
5. BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations
6. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
7. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
9. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
10. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
11. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Jan. 4, 2012   Unigene Laboratories, Inc. (OTCBB: ... manufacture and development of peptide-based therapeutics, announced that Ashleigh ... corporate overview at the Biotech Showcase™ 2012 in San ... a.m. PT (2:30 p.m. ET).  Mr. Palmer,s presentation will include ...
... Group, an international generic pharmaceuticals company, today announced ... Food & Drug Administration to market Methylphenidate Hydrochloride ... 40mg.  Actavis has first-to-file exclusivity on the 20mg, ... has commenced.  Methylphenidate Hydrochloride Extended-Release ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity 2
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
(Date:4/22/2014)... . , Reactive ... mode of action is complex: In low concentrations they ... at high concentrations they can cause "oxidative stress", which ... signaling unfolds in single cells and organelles in real-time, ... by the teams of LMU Professor Martin Kerschensteiner and ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2
... than in for-profit residences, review finds , WEDNESDAY, Aug. ... care than for-profit facilities, say Canadian researchers who reviewed ... , Forty studies found that non-profit nursing homes provided ... for-profit homes delivered better care. The remaining studies had ...
... , , FRIENDSWOOD, Texas, Aug. ... develops, manages and owns faith-based senior living facilities, today announced the ... development of a new senior living facility in the Houston, Texas ... $10 million senior living facility in Katy, Texas, should be available ...
... , , , NASHVILLE, ... payment cycle management solutions, today announced the implementation of its ... Group. The Sentinel Group, a recognized leader in healthcare fraud ... 5, 2009. , , The Sentinel ...
... NANJING, China, Aug. 5 /PRNewswire-Asia/ -- ... manufacturer and supplier of branded generic and,innovative anti-cancer pharmaceuticals ... 2009 second quarter results on Monday, August 17, 2009,after ... executive,officer, Jinsheng Ren, and chief financial officer, Frank Zhigang ...
... INDIANAPOLIS, Aug. 5 In the midst of the down economy, ... worse - forcing them to make difficult sacrifices to afford medications ... On Aug. 1, 2009, Lilly USA adjusted the income ... enrollment of eligible patients with incomes at or less than 300 ...
... , HACKENSACK, N.J., Aug 5 ReGen Biologics, a ... regarding its Menaflex collagen meniscus implant that were made in a ... party unaffiliated with the company. ReGen was unaware of ... on the Internet. The statements made in the release do ...
Cached Medicine News:Health News:Not-For-Profit Nursing Homes Fare Better in Studies 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 2Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 4Health News:Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 3Health News:ReGen Biologics Clarifies Recent Press about the Menaflex Device 2
Acetate Plate Sealers 100/Box...
... Microseal 'B' seals provide an adhesive-based sealing ... The aggressive adhesive layer ensures secure sample ... and tight sealing during thermal cycling when ... lid. The perforated end-tabs can be removed ...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
Inquire...
Medicine Products: